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Abstract Rotavirus (RV) is a frequent cause of severe
gastroenteritis (GE) in children. With the licensure of new
RV vaccines, data on the burden of disease are important
regarding immunization strategies. We reviewed the med-
ical records of children hospitalized with RV infection in
our institution between July 2002 and March 2006.
Relevant data were extracted in a standardized fashion
from records of hospitalized children with a positive RV
antigen test in a stool sample. Severity of disease was
graded by the 20-point Vesikari score. Population data were
obtained from the Federal Office of Statistics. Six hundred
eighty-six RVGE were identified and records of 608
hospitalizations (in 607 children) were available. In 539
(89%) cases, RVGE was the primary reason for hospitali-
zation and 69 (11%) were nosocomial infections; yearly
peaks occurred between February and May. Cumulative
incidence of RVGE was 26.7/1,000 children <3 years of
age. Median age of 539 children (55.6% male) with
primary RVGE was 1.4 years and median stay in the
hospital for both community acquired and nosocomial
RVGE was 4 days (interquartile range 3–5). Thirtypercent
and 94% of RV hospitalizations were in children <1 and
<3 years of age, respectively. Mean Vesikari score was 15
(range 6–20; 96% >11). Intravenous fluids were adminis-
tered in 378 (70%) patients, 130 (24%) patients were
rehydrated via nasogastral tube, and 31 (5.7%) received
rehydration by mouth. RVGE causes a substantial burden in
children with an estimated risk for hospitalization due to
RVGE of one in 37 children <3 years of age.
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Introduction
Diarrhea remains one of the most important global public
health challenges [17]. Human rotavirus (RV), an important
causative agent of severe gastroenteritis in infants and
young children worldwide, leads to high morbidity in both
developing and developed countries and high mortality in
developing countries. In developing countries, approxi-
mately 440,000 deaths are caused by RV each year. A
model developed by the Centers for Disease Control and
Prevention (CDC) to evaluate the global burden of RV
disease estimated that more than 220,000 hospitalizations
and 1.7 million out-patient visits were attributable to RV
each year in industrialized countries, including Europe,
USA, Japan, and Australia. A further seven million cases of
RV infections were managed entirely at home [23].
In developed countries, the disease usually is mild and
rarely leads to death. Nevertheless, RV has a major impact
on the quality of life of infected infants and children, their
parents, and families [14].
Studies of the disease burden of RV conducted in Europe
and the USA have included retrospective studies of diar-
rheal hospitalization [8, 13, 28], laboratory-based studies
[28, 30], reviews of published and unpublished data [18,
25], and analyses of cost effectiveness [29]. Data about RV
morbidity in Europe are available mainly for southern [2, 9,
26], northern [16, 31], and western parts [1, 3, 6, 11, 28].
Only a few studies were performed in eastern Europe [22].
In most countries, detection of RV is not notifiable, and
disease estimates are frequently based on laboratory data or
hospital discharge data. Of note, the incidence of
community-acquired RV infections remains unknown and
that of nosocomial RV infections might be underestimated
in studies based solely on hospital discharge data.
Examples of rates of hospitalization for RV infection in
children <5 years of age are one in 40 in the UK [28], one
Eur J Pediatr (2009) 168:1343–1348
DOI 10.1007/s00431-009-0934-z
S. Wildi-Runge : S. Allemann :U. B. Schaad :U. Heininger (*)
University Children’s Hospital (UKBB),
P.O. Box, 4005 Basel, Switzerland
e-mail: Ulrich.Heininger@ukbb.ch
in 33 in Finland [33], one in 73 in the general US population
[13], one in 100 in Germany [10], and one in 132 in the
region of Berne, Switzerland [6].
RV vaccines have been developed to reduce the
morbidity associated with severe RV diarrhea. A live oral
vaccine was introduced in the USA in 1998 [15, 25] but
was withdrawn soon thereafter because of its association
with intussusceptions [7]. Today, two new live-attenuated,
oral vaccines are available for use in young infants, up to
6 months of age, in many countries: a pentavalent bovine-
derived RV vaccine and a monovalent human-derived RV
vaccine [4, 32]. With the recent licensure of these new
vaccines, local data on the current burden of RV disease are
important for decisions regarding immunization strategies
[34]. To obtain such data, we reviewed the medical records
of all children hospitalized in our institution (which provides
primary, secondary, and tertiary care for the population in
Northwestern Switzerland) with laboratory confirmed RV
infection between January 2002 and March 2006.
Materials and methods
Patients were identified from two data sources: (1)
laboratory log books for rotavirus antigen testing (Diarlex®
Rota, Orion Diagnostica, Finland) and (2) the hospital
inpatient data base (ICD-10-Code “A 08.0 Rotavirus
Enteritis”). Relevant data (e.g., age, gestational age, gender,
signs and symptoms of infection, treatment) were extracted
in a standardized fashion from records of all patients with a
positive RV antigen test in a stool sample hospitalized
between January 2002 and March 2006. Severity of disease
was graded with the use of the 20-point Vesikari score [27].
Annual incidence of hospitalization was calculated based
on population data obtained from the Federal Office of
Statistics [5].
On a routine basis, stool specimens were collected from
all children hospitalized due to gastroenteritis or with new
onset of gastroenteritis during hospitalization and tested for
RV with an enzyme immunoassay (Diarlex® Rota, Orion
Diagnostica).
Primary RV gastroenteritis was defined as cases where
gastroenteritis was the leading cause for hospitalization.When
onset of gastroenteritis occurred during hospitalization,
possible nosocomial infection was assumed if this occurred
24–48 h after hospitalization and definite nosocomial infec-
tion was assumed if this occurred >48 h after hospitalization.
We used SPSS Software 13.0 for Windows for statistical
analyses. Differences between proportions were assessed by
the chi-square test. The adopted level of significance was
<0.05. The study was approved by the University's Ethics
Committee.
Fig. 1 Seasonal distribution of
RV infections by month (July to
June) and study year
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Results
General characteristics
A total of 686 cases were identified and records of 608
hospitalizations (in 607 children) were available for
analysis. Of these, 539 (88.7%) were community acquired,
21 (3.5%) were possible and 30 (4.9%) were definite
nosocomial infections. In the remaining 18 cases, docu-
mentation was insufficient for classification.
The mean age of patients with primary RV gastroenteritis
(55.6% male) was 1.4 years and the cumulative incidence of
RV hospitalizations was 26.7/1,000 children under 3 years of
age. RV gastroenteritis had a strong seasonality with yearly
peaks between February and May (Fig. 1). The median stay
in hospital was 4 days (interquartile range 3–5) for both
community acquired and nosocomial RV gastroenteritis. Of
RV hospitalizations, 30% and 94% were in children under 1
and under 3 years of age, respectively.
There were proportionally more children with foreign
nationality hospitalized with primary RV gastroenteritis
(46.4%) when compared to all children living in the cantons
of Basel (32.3%).
Clinical characteristics
Relevant clinical characteristics for primary and nosocomial
RV gastroenteritis are demonstrated in Table 1. Of 539
patients with primary RV gastroenteritis, 127 (23.6%) had
persistent diarrhea for more than 5 days and 272 (50.5%)
had concomitant vomiting for >2 days. A body temperature
≥39°C was documented in 252 (46.8%) patients. Dehydra-
tion (>5% loss of body weight) was observed in 461
(85.5%) patients. Patients without dehydration were hospi-
talized due to feeding difficulties. Severity of disease was
less pronounced in nosocomial infections with lower
percentages of patients with vomiting for >2 days and
dehydration ≥5% (Table 1).
Hundred and four (19.3%) of 539 patients with primary
RV gastroenteritis had concomitant signs or symptoms of
upper airway infections including 39 patients (7.2%) with
an acute otitis media; further, 11 (2%) patients presented
with bronchitis.
Seventy (13.0%) of 539 patients hospitalized with
primary RV gastroenteritis had underlying chronic diseases
and one of them died during hospitalization. This was a
13-month-old boy with autoimmune hemolytic anemia and
Table 1 Comparison of clinical characteristics of community acquired versus nosocomial RV gastroenteritis
Signs and symptoms Community acquired (N=539) Nosocomial (N=51) Odds ratio (95% CI) p value
N/N known (%) N/N known (%)
Any vomiting (days)
1 134/519 (24.9) 8/39 (16.0)
2 113/519 (21.0) 8/39 (16.0)
>2 272/519 (50.5) 23/39 (45.0) 0.8 (0.7–1.2) 0.63
Vomiting: frequency/day (maximum)
1 38/519 (7.1) 7/39 (14.0)
2 56/519 (10.4) 14/39 (28.0)
>2 425/519 (78.8) 18/39 (35.0) 5.3 (2.6–10.8) 0.001
Any diarrhea (days)
1–4 318/530 (59.0) 33/47 (65.0)
5 85/530 (15.8) 5/47 (10.0)
>5 127/530 (23.6) 9/47 (18.0) 1.3 (0.6–3.0) 0.46
Diarrhea: frequency/day (maximum)
1–3 174/531 (32.2) 24/47 (47.0)
4–5 166/531 (30.8) 12/47 (24.0)
>5 191/531 (35.4) 11/47 (22.0) 1.8 (0.9–3.9) 0.08
Body temperature (°C)
37.1–38.4 202/536 (37.5) 13/47 (26.0)
38.5–38.9 79/536 (14.7) 11/47 (22.0)
≥ 39 252/536 (46.8) 23/47 (45.0) 0.9 (0.5–1.8) 0.80
Dehydration (%)
No 38/538 (7.1) 28/49 (55.0)
<5% 39/538 (7.2) 4/49 (8.0)
≥5% 461/538 (85.5) 17/49 (33.0) 11.3 (5.7–22.4) <0.001
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thrombocytopenia who died from cardiac shock due to
intractable gastrointestinal bleeding in association with RV
gastroenteritis.
The mean Vesikari score in patients with primary RV
gastroenteritis was 15.3 (range 6–20) and 519 (96.3%)
patients had a score ≥11, generally considered as “severe
disease” (Fig. 2). In patients with possible and definite
nosocomial infections, mean Vesikari scores were 13.1 and
11.7, respectively (differences not significant).
The mean Vesikari score in patients with underlying
diseases and primary healthy patients were similar (15.1
versus 15.0) and the mean duration of hospitalization was
identical (4.7 days). Forty (98.0%) of 41 pre-term infants
and 411 (96.5%) of 426 full-term infants with primary RV
gastroenteritis had Vesikari scores >11 (p=0.89).
Treatment of RV gastroenteritis
Of 539 patients with primary RV gastroenteritis, 378 (70.1%)
required i.v. fluids, 130 (24.1%) were orally rehydrated via a
nasogastral tube, and 31 (5.7%) received oral rehydration.
Only three patients required intensive care treatment.
Laboratory results
Among patients with primary RV gastroenteritis, 84.8% (457
of 534) had signs of acidosis in a capillary blood gas analysis
(i.e., base excess <−5 and/or pH <7.35) on admission. The
white blood cell account revealed leukocytosis (≥15,000
leukocytes/µl) in 14.8% (80 of 431) patients and CRP was
elevated (>5 mg/l) in 36.9% (199 of 424) patients.
Discussion
Each year, RV causes approximately 111 million episodes
of gastroenteritis worldwide with a peak between 6 months
to 2 years of age, 25 million clinic visits, two million
hospitalizations, and 352,000–592,000 deaths. By the age
of 5 years, almost every child has had one or more episodes
of RV gastroenteritis of which one in five led to a clinic
visit, one in 65 to hospitalization, and approximately one in
293 to death [23].
In the present study, 94% of hospitalizations due to
RV gastroenteritis occurred in children <3 years with a
cumulative incidence of 26.7/1,000 children in this age
group. This is in the range of similar previous investigations in
various other countries (11.1 to 36/1,000) [20, 21, 28]. When
compared to the recent study in the region of Berne, where
one in 132 children <5 years of age was hospitalized because
of RV gastroenteritis, our proportion (one in 37 children
<3 years of age) was higher [6]. This variability may be
explained by differences in study designs and periods, living
conditions, and social behaviors. Several observations
indicate that RV-coded discharges likely capture only a
fraction of all RV hospitalizations [21, 28]. Our study design,
where all laboratory tests for RV infection were screened,
makes it unlikely that a significant number of cases have
been missed.
As expected, median age of our patients was low
(1.4 years) and 30% of cases occurred in infants. This
reflects the known epidemiology of RV gastroenteritis and
is also in agreement with a previous study from members of
our group in the ambulatory sector, where the mean age of
patients with RV gastroenteritis was 1.5 years [19].
Similarly, Velazquez et al. showed that the incidence of
any type of rotavirus infection is generally highest among
infants 6–14 months old and decreases in children 21–
23 months old. They also reported a high incidence of
reinfection which, however, usually is mild [30]. Accord-
ingly, only one of 607 children in our case series was
hospitalized twice for RV gastroenteritis.
Complications caused by RV infection were rare and no
deaths causally related to RV infection occurred, although
one child with underlying disease died while suffering from
nosocomial RV gastroenteritis.
In Europe, yearly RV seasons start in Spain during
December and progresses towards the northeast, reaching
The Netherlands and Finland byMarch [23]. Accordingly, we
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Fig. 2 Vesikari scores in patients with primary RV gastroenteritis
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RV gastroenteritis is associated with a significant burden
for patients and parents, medical staff, and society [14, 21].
The associated costs of any disease are very dependent on
the seriousness of the illness, but also on the level of
patient's dependence. It is important to underline that the
main burden of hospitalization due to RV gastroenteritis is
with children under 2 years of age [11, 12, 20, 24].
Approximately 10% of RV infections were nosocomial
and these cases tended to be less severe than those acquired
in the community. This is not surprising as only a minority
of RV infections per se require hospitalization and many
cases acquired during hospitalization could have been dealt
with in an ambulatory setting.
Our study has strengths and some limitations. As a
strength, case ascertainment was comprehensive with two
independent data sources and the fact that in-house antigen
testing for rotavirus is standard care in children hospitalized
with gastroenteritis in our institution. Further, the study
period covered almost 4 years and therefore is likely to be
representative.
As a limitation, no comparisons with RV negative episodes
of gastroenteritis were performed. However, it is well known
that these are less severe than RV gastroenteritis [23]. Further,
as with any retrospective study design, data need to be
interpreted with caution.
Conclusion
RV gastroenteritis causes a substantial burden for infants
and young children and their families in our area. This
population based data provide a basis for individual
decisions regarding immunization against rotavirus and can
guide pediatricians in order to promote RV vaccination in
their patients, which has been recommended by a European
expert group recently [34].
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